Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter retrospective cohort study evaluating novel and conventional salvage therapies (ST) in Relapsed Refractory Classic Hodgkin Lymphoma after Autologous Stem Cell Transplant

Next Previous
Trial Profile

A multicenter retrospective cohort study evaluating novel and conventional salvage therapies (ST) in Relapsed Refractory Classic Hodgkin Lymphoma after Autologous Stem Cell Transplant

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bendamustine (Primary) ; Brentuximab vedotin (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Cytarabine (Primary) ; Dexamethasone (Primary) ; Etoposide (Primary) ; Gemcitabine (Primary) ; Ifosfamide (Primary) ; Methylprednisolone (Primary) ; Nivolumab (Primary) ; Antineoplastics
  • Indications Hodgkin's disease
  • Focus Therapeutic Use

Most Recent Events

  • 01 Mar 2023 Final results published in the American Journal of Hematology.
  • 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
  • 04 Feb 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top